WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) View the PDF document
Table of Contents
Close this folderREGULATORY MATTERS
View the documentACETYLSALICYLIC ACID - MHRA confirms labelling change
View the documentACITRETIN - Warnings of depression added to label
View the documentASTEMIZOLE - Withdrawn due to life-threatening ventricular arrhythmias
View the documentCAMELIA SINENSIS - Ethanolic extract products withdrawn due to hepatotoxicity
View the documentDIETARY SUPPLEMENTS - Withdrawal of two products due to presence of sildenafil
View the documentHUA FO - Presence of tadalafil
View the documentIODINE - Some products contain more than the RDA
View the documentLEVODOPA/CARBIDOPA - New warning about somnolence and sudden onset sleep
View the documentLINDANE - Additional warnings and medication guide added to label
View the documentNEFAZODONE - Regulatory status update
View the documentNIMESULIDE - Paediatric preparations banned in Bangladesh
View the documentPERGOLIDE MESYLATE - Risk of cardiac valvulopathy
View the documentREPAGLINIDE - Contraindicated with gemfibrozil
View the documentRISPERIDONE - Prescribing information updated to reflect cardiovascular adverse events
View the documentTELITHROMYCIN - Aggravation of myasthenia gravis
Open this folder and view contentsSAFETY OF MEDICINES
Open this folder and view contentsCURRENT CONCERNS
Open this folder and view contentsDRUGS OF INTEREST
Open this folder and view contentsFEATURE
 

HUA FO - Presence of tadalafil

Canada. Health Canada is warning consumers not to use Hua Fo VIGOR-MAX Tablets, a Chinese Herbal product that contains tadalafil. Tadalafil is a prescription drug approved for sale for male erectile dysfunction in the UK, Germany, Sweden, Denmark, Finland, New Zealand, Australia and Singapore. It is not approved for sale in Canada. Inappropriate use of tadalafil could cause severe adverse reactions. Tadalafil should not be used by individuals who are taking any medication or other products containing nitrates: concurrent use could result in the development of potentially life-threatening low blood pressure. Also, tadalafil should not be used by patients with severe renal or hepatic insufficiency. Health Canada issued a previous warning in February 15, 2002 (WHO Pharmaceuticals Newsletter No. 2, 2002) concerning Hua Fo when it was found to contain sildenafil. At the time, Health Canada required the importer to remove the product from the shelves. Health Canada is again directing the importer to remove Hua Fo VIGOR-MAX from the market and has issued a Customs Alert to stop its further importation.

Reference:

Health Canada Warnings/ Advisories, 27 May 2003. Available from URL: http://www.hc-sc.gc.ca

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018